IRIS
BRUNETTI, ORONZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.936
AS - Asia 1.314
EU - Europa 766
SA - Sud America 320
AF - Africa 40
OC - Oceania 3
AN - Antartide 1
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.381
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.896
SG - Singapore 553
CN - Cina 307
BR - Brasile 278
SE - Svezia 222
HK - Hong Kong 198
RU - Federazione Russa 154
VN - Vietnam 100
DE - Germania 80
GB - Regno Unito 65
IT - Italia 64
FR - Francia 49
IN - India 41
FI - Finlandia 36
BE - Belgio 25
ID - Indonesia 25
CA - Canada 23
AR - Argentina 22
PL - Polonia 16
CI - Costa d'Avorio 15
TR - Turchia 13
BD - Bangladesh 10
CZ - Repubblica Ceca 9
JP - Giappone 9
MX - Messico 9
UA - Ucraina 9
ZA - Sudafrica 9
ES - Italia 8
EC - Ecuador 6
IR - Iran 6
AE - Emirati Arabi Uniti 5
IQ - Iraq 5
PK - Pakistan 5
AT - Austria 4
IL - Israele 4
KR - Corea 4
MA - Marocco 4
NL - Olanda 4
NP - Nepal 4
PY - Paraguay 4
VE - Venezuela 4
AU - Australia 3
CH - Svizzera 3
CO - Colombia 3
IE - Irlanda 3
JO - Giordania 3
KZ - Kazakistan 3
SA - Arabia Saudita 3
UZ - Uzbekistan 3
AO - Angola 2
BH - Bahrain 2
CR - Costa Rica 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
EG - Egitto 2
ET - Etiopia 2
JM - Giamaica 2
KE - Kenya 2
KW - Kuwait 2
LT - Lituania 2
QA - Qatar 2
RS - Serbia 2
TN - Tunisia 2
AL - Albania 1
AQ - Antartide 1
AZ - Azerbaigian 1
BB - Barbados 1
BG - Bulgaria 1
BJ - Benin 1
BO - Bolivia 1
BY - Bielorussia 1
CL - Cile 1
HN - Honduras 1
HR - Croazia 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LU - Lussemburgo 1
MT - Malta 1
NO - Norvegia 1
PE - Perù 1
PH - Filippine 1
PS - Palestinian Territory 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
TG - Togo 1
TH - Thailandia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 6.381
Salva come PNG Salva come JPEG
Città #
Fairfield 519
Ashburn 458
Chandler 443
Singapore 285
Woodbridge 282
Seattle 251
Cambridge 220
Houston 212
Hong Kong 194
Nyköping 182
Wilmington 170
Beijing 110
Ann Arbor 108
Dearborn 103
Dallas 68
New York 62
Lawrence 57
Roxbury 55
Los Angeles 44
Munich 41
Brooklyn 37
Des Moines 35
Ho Chi Minh City 32
São Paulo 30
Nanjing 29
The Dalles 28
Boardman 27
San Diego 25
Brussels 24
Dong Ket 24
Moscow 24
Columbus 22
Jakarta 21
Bari 19
Santa Clara 19
Turku 19
Council Bluffs 18
Paris 17
Hanoi 16
Abidjan 15
Inglewood 15
Hefei 14
Chennai 13
Pune 13
Warsaw 13
Helsinki 12
Phoenix 11
Buffalo 10
London 10
Marseille 10
Shanghai 10
Montreal 9
Tokyo 9
Chicago 8
Denver 8
Frankfurt am Main 8
Guangzhou 8
Jinan 8
San Mateo 8
Da Nang 7
Düsseldorf 7
Nuremberg 7
Poplar 7
Rio de Janeiro 7
Stockholm 7
Augusta 6
Belo Horizonte 6
Brno 6
Campinas 6
Edinburgh 6
Jacksonville 6
Johannesburg 6
Orem 6
San Francisco 6
Atlanta 5
Blumenau 5
Curitiba 5
Kilburn 5
Kunming 5
Manchester 5
Monmouth Junction 5
Princeton 5
Toronto 5
Washington 5
Zhengzhou 5
Ankara 4
Ardabil 4
Asunción 4
Dhaka 4
Goiânia 4
Manfredonia 4
Mumbai 4
New Bedfont 4
Porto Alegre 4
Salvador 4
Seoul 4
Wuhan 4
Amman 3
Boston 3
Brasília 3
Totale 4.750
Salva come PNG Salva come JPEG
Nome #
Mast cells and angiogenesis in pancreatic ductal adenocarcinoma 231
Angiogenesis in adenosquamous cancer of pancreas 195
Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue 170
CAFs and TGF-β Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer 159
Fisiologia V Ed. 155
Emerging role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma 154
Targeting angiogenesis in biliary tract cancers: An open option 152
Inflammatory cells infiltrate and angiogenesis in locally advanced and metastatic cholangiocarcinoma 149
Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells 148
Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview 144
Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma 144
Bone metastasis as primary presentation of pancreatic ductal adenocarcinoma: A case report and literature review 143
Bone metastases in biliary cancers: A multicenter retrospective survey 141
Strategies to improve cancer immune checkpoint inhibitors efficacy, other than abscopal effect: A systematic review 138
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol 136
Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma 133
Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance 132
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 131
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 130
Systematic review of irreversible electroporation role in management of locally advanced pancreatic cancer 127
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 126
Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma 122
Long‐term survival of an advanced colorectal cancer patient treated with Regorafenib: Case report and literature review 120
Multimodal treatment of resectable pancreatic ductal adenocarcinoma 117
Micro-RNA in pancreatic adenocarcinoma: Predictive/prognostic biomarkers or therapeutic targets? 116
Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib 115
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 109
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 109
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 107
Immunotherapy for colorectal cancer: where are we heading? 106
Molecular characterization of a long-term survivor double metastatic non-small cell lung cancer and pancreatic ductal adenocarcinoma treated with gefitinib in combination with gemcitabine plus nab-paclitaxel and mFOLFOX6 as first and second line therapy 106
The potential predictive role of nuclear NHERF1 expression in advanced gastric cancer patients treated with epirubicin/oxaliplatin/capecitabine first line chemotherapy 105
Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors 101
Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? 99
Management of patients with end-stage renal disease undergoing chemotherapy: Recommendations of the Associazione Italiana di Oncologia Medica (AIOM) and the Società Italiana di Nefrologia (SIN) 98
The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following? 98
Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials 97
COVID-19 Infection in Cancer Patients: How Can Oncologists Deal With These Patients? 96
Bone metastases in hepatocellular carcinoma: an emerging issue 96
Cytotoxic t-lymphocyte antigen-4 in colorectal cancer: Another therapeutic side of capecitabine 96
Immunological mutational signature in adenosquamous cancer of pancreas: an exploratory study of potentially therapeutic targets 90
Basics and frontiers on pancreatic cancer for radiation oncology: Target delineation, SBRT, SIB technique, MRgRT, particle therapy, immunotherapy and clinical guidelines 87
Expression and characterization of a novel recombinant cytotoxin II from Naja naja oxiana venom: A potential treatment for breast cancer 86
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 85
Somatic BRCA Mutation in a Cholangiocarcinoma Patient for HBOC Syndrome Detection 84
null 81
Clinical practice guidelines for diagnosis, treatment and follow-up of exocrine pancreatic ductal adenocarcinoma: Evidence evaluation and recommendations by the italian association of medical oncology (AIOM) 81
Paraneoplastic focal segmental glomerulosclerosis in sarcomatoid renal cell cancer. 79
Immune system and bone microenvironment: rationale for targeted cancer therapies 76
Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma: Could Surgery Represent a Therapeutic Option? 76
null 67
NLRP3 Inflammasome From Bench to Bedside: New Perspectives for Triple Negative Breast Cancer 65
A scoping review on the potentiality of PD-L1-inhibiting microRNAs in treating colorectal cancer: Toward single-cell sequencing-guided biocompatible-based delivery 64
The latest findings of PD-1/PD-L1 inhibitor application in gynecologic cancers 63
null 61
Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies 61
Is it Time for a Therapeutic Algorithm in Resected Pancreatic Ductal Adenocarcinoma? 46
Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis 46
On the Management of Drug Interactions in the Course of Concomitant Treatments for COVID-19 and Antineoplastic Agents 43
Moving the target on the optimal adjuvant strategy for resected pancreatic cancers: A systematic review with meta-analysis 42
Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel? 39
The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead 37
Identification of Common and Distinct Pathways in Inflammatory Bowel Disease and Colorectal Cancer: A Hypothesis Based on Weighted Gene Co-Expression Network Analysis 2
Totale 6.612
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.526
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.526
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021490 0 0 0 0 0 70 72 76 45 87 75 65
2021/2022509 42 19 13 15 20 45 17 30 37 46 68 157
2022/2023929 104 155 85 75 85 95 15 113 140 5 40 17
2023/2024324 19 59 15 28 33 95 7 9 3 7 3 46
2024/20251.210 53 11 85 51 47 111 103 107 44 79 197 322
2025/20261.325 405 115 168 281 326 30 0 0 0 0 0 0
Totale 6.612